Skip to main content
NewslettersWatchlist

Eupraxia Pharmaceuticals Inc(EPRX-T)
TSX

Today's Change
Real-Time Last Update
Day Low3.99
Day High4.00
Open:4.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Eupraxia Pharmaceuticals Inc down on Thursday (EPRX)
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Newswire.ca
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Newswire.ca
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Newswire.ca
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.\
Newswire.ca
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
Newswire.ca
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
Newswire.ca
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
GlobeNewswire
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
GlobeNewswire
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million
GlobeNewswire
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million
Newswire.ca
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
The Globe and Mail
Friday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
Newswire.ca
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee
Newswire.ca
Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus
AI-generated - The Globe and Mail
Eupraxia Pharmaceuticals:Stocks Analysts Recently Upgraded on TSX (EPRX)

Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.